Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
Rebecca A Herbertson, Niall C Tebbutt, Fook-Thean Lee, David J MacFarlane, Bridget Chappell, Noel Micallef, Sze-Ting Lee, Timothy Saunder, Wendie Hopkins, Fiona E Smyth, David K Wyld, John Bellen, Daryl S Sonnichsen, Martin W Brechbiel, Carmel Murone, Andrew M Scott
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2009
Awarded by NATIONAL CANCER INSTITUTE
Wyeth Pharmaceuticals, Inc. provided financial support and pharmaceutical investigation compound CMD-193 for the study. The Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research supports Martin W. Brechbiel.